Biotechnology firm Galapagos said on Tuesday it would wind down its cell therapy business after attempts to sell it were unsuccessful, affecting 365 jobs in Europe, China and the U.S.
Claude for Life Sciences is based on Anthropic’s most powerful large language model Claude Sonnet 4.5. It’s designed to ...
Investors have grown more cautious about putting their money into the inherently unpredictable drug development industry.
The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and ...
CRMD, CELC, RANI, and RAPT are pushing aggressively to the upside on Monday. Here's what is driving these four biotech stocks ...
Elliot Maza’s professional journey reflects the intersection of law, finance, and biotechnology, but it is also deeply rooted ...
Acadia Pharmaceuticals CEO Catherine Owen Adams breaks down the company’s recent rebrand, its expansion into rare disease marketing and how it’s using AI.
Australia globally recognised for world-class life sciences but needs more funding from investors to support companies at ...
In 2025, biotech machines are getting smarter and more connected. Think of machines that can run by themselves more, learn ...
The massive AI deals and capital spending plans announced by some of the top technology companies have stunned many on Wall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results